Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Kathleen Steemans"'
Autor:
Thomas K van der Made, Jan Snoeys, Lieve Dillen, Ils Pijpers, Daniel Scotcher, Aleksandra Galetin, Sophie Jonkers, Mario Monshouwer, Amin Rostami-Hodjegan, Frank Jacobs, Annett Kunze, Kathleen Steemans, An Tuytelaars, Marie-Emilie Willemin
Publikováno v:
Willemin, M, Van Der Made, T K, Pijpers, I, Dillen, L, Kunze, A, Jonkers, S, Steemans, K, Tuytelaars, A, Jacobs, F, Monshouwer, M, Scotcher, D, Rostami-hodjegan, A, Galetin, A & Snoeys, J 2021, ' Clinical Investigation on Endogenous Biomarkers to Predict Strong OAT-Mediated Drug–Drug Interactions ', Clinical Pharmacokinetics . https://doi.org/10.1007/s40262-021-01004-2
BackgroundEndogenous biomarkers are promising tools to assess transporter-mediated drug–drug interactions early in humans.MethodsWe evaluated on a common and validated in vitro system the selectivity of 4-pyridoxic acid (PDA), homovanillic acid (HV
Autor:
Marie-Emilie Willemin, Thomas K. Van Der Made, Ils Pijpers, Lieve Dillen, Annett Kunze, Sophie Jonkers, Kathleen Steemans, An Tuytelaars, Frank Jacobs, Mario Monshouwer, Daniel Scotcher, Amin Rostami-Hodjegan, Aleksandra Galetin, Jan Snoeys
Publikováno v:
Clinical Pharmacokinetics. 61:463-463
Autor:
Filip Cuyckens, Geert Mannens, Andrés Francesch, Kathleen Steemans, Pablo Aviles, Jos M. Van Houdt, Alex Hemeryck, Roland De Coster, Marc Bockx, Marc Vermeir
Publikováno v:
Biochemical Pharmacology. 77:1642-1654
Trabectedin (YONDELIS ® ) is a potent anticancer agent which was recently approved in Europe for the treatment of soft tissue sarcoma. The drug is currently also in clinical development for the treatment of ovarian carcinoma. In vitro experiments we